{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:37:50Z","timestamp":1789850270175,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bbmt.2018.07.019","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:34:19Z","timestamp":1532046859000},"page":"2265-2270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-9252","authenticated-orcid":false,"given":"Annalisa","family":"Paviglianiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9699-3462","authenticated-orcid":false,"given":"Karina","family":"Tozatto Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Gehlkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Gac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Yves","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Abecasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhan","family":"Gurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Lopez","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Volt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kenzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Paul","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Gluckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.07.019_bib0001","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0002","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2141.2010.08492.x","article-title":"Allogeneic transplantation for Hodgkin's lymphoma","volume":"152","author":"Corradini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bmt.1705977","article-title":"Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation","volume":"41","author":"Thomson","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0004","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"98","author":"Gibb","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2119","article-title":"Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and\/or refractory Hodgkin's lymphoma","volume":"32","author":"Garciaz","year":"2014","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0008","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"28","author":"Bek\u00f6z","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/bmt.2014.259","article-title":"Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor","volume":"50","author":"Bachanova","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0011","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2016.349","article-title":"Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"52","author":"Gauthier","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0012","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0013","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0014","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-1146-3","article-title":"Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma","volume":"90","author":"Chen","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0016","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0017","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0018","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17474086.2018.1449637","article-title":"Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma","volume":"11","author":"Kallam","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bbmt.2008.11.013","article-title":"Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation","volume":"15","author":"Brunstein","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0022","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0023","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood-2005-09-3827","article-title":"Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma","volume":"107","author":"Majhail","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2007.15.8865","article-title":"Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Rodrigues","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ejh.12557","article-title":"Umbilical cord blood transplantation in adults with advanced Hodgkin's disease: high incidence of post-transplant lymphoproliferative disease","volume":"96","author":"Pi\u00f1ana","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0026","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3109\/10428194.2015.1105370","article-title":"Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma","volume":"57","author":"Thompson","year":"2016","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0027","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","article-title":"Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma","volume":"49","author":"Raiola","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0028","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0029","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"Mariotti","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2017.10.040","article-title":"Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia","volume":"24","author":"Hsu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0031","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report","volume":"Mar 14","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0032","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O'Connor","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0033","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0034","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.07.019_bib0035","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118304075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118304075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:27Z","timestamp":1761059067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118304075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1083879118304075"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.019","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}